Oxidative Medicine and Cellular Longevity

Oxidative Medicine and Cellular Longevity / 2017 / Article
Special Issue

Oxidants and Redox Signaling: Perspectives in Cancer Therapy, Inflammation, and Plasma Medicine

View this Special Issue

Research Article | Open Access

Volume 2017 |Article ID 4396467 | 12 pages | https://doi.org/10.1155/2017/4396467

Toxicity and Immunogenicity in Murine Melanoma following Exposure to Physical Plasma-Derived Oxidants

Academic Editor: Peeter Karihtala
Received03 Mar 2017
Accepted04 May 2017
Published27 Jun 2017

Abstract

Metastatic melanoma is an aggressive and deadly disease. Therapeutic advance has been achieved by antitumor chemo- and radiotherapy. These modalities involve the generation of reactive oxygen and nitrogen species, affecting cellular viability, migration, and immunogenicity. Such species are also created by cold physical plasma, an ionized gas capable of redox modulating cells and tissues without thermal damage. Cold plasma has been suggested for anticancer therapy. Here, melanoma cell toxicity, motility, and immunogenicity of murine metastatic melanoma cells were investigated following plasma exposure in vitro. Cells were oxidized by plasma, leading to decreased metabolic activity and cell death. Moreover, plasma decelerated melanoma cell growth, viability, and cell cycling. This was accompanied by increased cellular stiffness and upregulation of zonula occludens 1 protein in the cell membrane. Importantly, expression levels of immunogenic cell surface molecules such as major histocompatibility complex I, calreticulin, and melanocortin receptor 1 were significantly increased in response to plasma. Finally, plasma treatment significantly decreased the release of vascular endothelial growth factor, a molecule with importance in angiogenesis. Altogether, these results suggest beneficial toxicity of cold plasma in murine melanomas with a concomitant immunogenicity of potential interest in oncology.

1. Introduction

With over 70,000 new incidences and 10,000 deaths annually in the U.S. alone, melanoma is a highly prevalent type of cancer [1]. Advances have been made in melanoma therapy in the past decade but stage IV survival of nonresponder patients is still poor [2]. This owes partly to melanomas having the highest mutational burden but at the same time also having the most neoantigens among all types of cancers in humans [3]. Similar to other types of cancer, the majority of patients die due to metastasis spreading throughout the body [4]. This requires an understanding of cellular behavior and motility in response to therapy [5]. BRAF, NRAS, and MEK inhibitors improved end-stage melanoma patient survival [6]. Melanoma immunotherapy with anti-PD-(L)1 and anti-CTLA-4 antibodies further revolutionized therapy by abolishing cancer immunosuppression of tumor-specific T cells [7]. Moreover, increased immunogenicity correlates with CD163+ cellular infiltrate that in combination with the number of FOXP3+ cells is a predictor of survival [8]. Immunogenic cell death (ICD) is hallmarked by expression of calreticulin [9] which makes tumor cells visible to the immune system [10]. Of note, mitochondrial-derived reactive oxygen species (ROS) and reactive nitrogen species (RNS) and subsequent oxidative events seem to contribute to some molecular ICD events following chemo- and radiotherapy [11].

Cold physical plasma is an ionized gas and potently generates ROS and RNS of different kinds [12]. Several studies indicated the involvement of mitochondria in plasma-mediated cancer cell death, underlining the notion that exogenous as well as endogenous reactive oxygen species may be at work [1315]. Accordingly, cold plasma has been suggested as an interesting tool in skin cancer [16] and generally in tumor therapy [17] before. The first work also pointed at the plasma’s potential to involve immunogenic cell death [18]. Interestingly, antioxidants were shown to enhance metastatic spreading in a murine melanoma model [19].

Hence, the effects of cold plasma-derived oxidants on cell motility, cytotoxicity, and immunogenicity were studied in murine melanoma cell line. It was found that all of these three important hallmarks of cancer were affected by exposure to plasma. These results are promising with regard to cold plasmas potentially having a future role in combination therapy in oncology.

2. Materials and Methods

2.1. Cell Culture and Plasma Treatment

Murine, metastatic B16F10 cells (ATCC CRL-6475) were maintained in Rosswell Park Memorial 1640 (RPMI1640) medium (Pan BioTech, Germany) containing 10% fetal bovine serum, 2% penicillin/streptomycin, and 1% glutamine (all Sigma, Germany). For plasma treatment in 24-well dishes (NUNC, Denmark), 5 × 104 cells were added per well. For treatment in 96-well plates (NUNC), 1 × 104 cells were given to each well. Cells were allowed to adhere overnight. As plasma source, an atmospheric pressure argon plasma jet (kINPen 11) was utilized. This plasma primarily acts via ROS and RNS and is not genotoxic [20, 21]. The device is technically similar to the kINPen MED that received accreditation as medical product for skin disease. Argon gas (99.999% pure; Air Liquide, France) was used to ignite the plasma at a frequency of about 1 MHz [22]. The jet was hovered over the cells for the indicated time using a computer-programed xyz-table (CNC, Germany).

2.2. Redox-Sensitive Probe and High-Content Imaging

Cells were loaded with CM-H2DCF-DA (Thermo Fisher, USA) and treated with plasma or were left untreated. Fluorescent microscopy (Observer Z.1; Zeiss, Germany) was employed to image dye fluorescence facilitated by intracellular oxidases. Quantification of the cells’ mean fluorescent intensities was facilitated using Fiji software. Metabolic activity was assessed by incubating the cells with 7-hydroxy-3H-phenox-azin-3-one-10-oxide (resazurin; Alfa Aesar, USA). Subsequently, fluorescent resorufin was quantified using a microplate reader measuring at λex 535 nm and λem 590 nm (Tecan, Switzerland). To assess viability visually, propidium iodide (PI; Sigma) was added, and cells were imaged with a high-content imaging device (Operetta CLS; Perkin-Elmer, Germany) at different time points following treatment. For each time point, the total number of cells was quantified using digital phase contrast (DPC), and the number of PI positive were expressed as percent of that. In a similar manner, the total growth area was calculated for different time points following plasma treatment. DPC was used to identify cells, and only viable cells were included in the analysis before normalization to untreated control was calculated. To quantify cell motility, cells were plasma-treated and subsequently imaged every 20 min over three hours. Only PI cells (identified using DPC) were tracked. Mean displacement per cell over time was calculated. To identify mean nuclear area per cell for each treatment, B16F10 melanomas were fixed with PBS/PFA (4%, Sigma), permeabilized with 0.1% Triton X 100 (Sigma), and stained with DAPI. Nuclei area was quantified using automated image analysis. A similar protocol was applied to quantify cytosolic mean fluorescence intensity of zonula occludens 1 (ZO1 antibody; AbCam, UK) protein. The cytosolic area was determined using DPC, and the nuclear area was subtracted from that. Data analysis was performed using Harmony 4.5 software (PerkinElmer).

2.3. Real-Time Deformability Cytometry

Real-time deformability cytometry (Zellmechanik, Germany) allows analyzing the mechanical properties of cells with a throughput of up to 1000 cells per second [23]. The setup is built around an inverted microscope (Zeiss Observer, Germany) having a PDMS-based microfluidic chip assembled on the translation stage. One to two hours after plasma treatment, the cell suspension was driven through the central constriction of the chip by a syringe pump (Nemesys; Cetoni, Germany) at different flow rates between 0.16 μl/s and 0.32 μl/s. Inside the constriction, cell deformation was induced by a laminar flow profile and recorded by a high-speed camera (MC1362; Mikrotron, Germany) at 2000 frames per second. Image analysis was done on the fly enabling the quantification of size and deformation for each cell. For sample preparation, cells were centrifuged and resuspended in PBS containing 0.5% (w/v) methylcellulose to a final concentration of 106 cells per ml. For each sample, at least 5000 events were acquired. An analytical model calculating the hydrodynamic flow profile around a cell inside the channel allows to link cell deformation to material properties [24] and derivation of the cells’ Young’s modulus [25]. Here, cell deformation is calculated from where A represents the area of the cell and l the perimeter. Statistical analysis was based on linear mixed models, which separates random effects, for example, biological variability, from fixed effects, for example, treatment of cells.

2.4. Cell Surface Marker Expression

Cells were detached using accutase (BioLegend, UK) and incubated with monoclonal antibodies directed against MHC I allophycocyanin (BioLegend), melanocortin receptor 1 (MC-1R) fluorescein isothiocyanate (Bioss, USA), and calreticulin (CRT) Alexa Fluor 647 (AbCam, UK). Cells were washed and resuspended in PBS containing 1% bovine serum albumin (Sigma) and 4′,6-diamidino-2-phenylindole (DAPI; Sigma). Cellular properties were acquired using multicolor flow cytometry (CytoFlex; Beckman-Coulter, Germany). Only viable (DAPI) cells were included for the analysis of cell surface marker mean fluorescent intensities. Kaluza 1.5a software (Beckman-Coulter) facilitated data analysis.

2.5. Vascular Endothelial Growth Factor

Cell culture supernatants were stored at −80 °C until analysis. Concentrations of vascular endothelial growth factor (VEGF) were assessed using an enzyme-linked immunosorbent assay (ELISA) kit (BMS619-2) according to the vendor’s instructions (eBioscience, Germany).

2.6. Statistics

Graphing and statistical analysis was performed using prism 7.02 (GraphPad Software, USA). Mean and standard errors were calculated and analyzed according to statistical methods given in the figure legends. Groups or treatments differing significantly were marked with asterisks (; ; and ).

3. Results

3.1. Plasma Oxidized Melanoma Cell and Decreased Metabolic Activity and Viability

Cold physical plasma generated many different kinds of oxidants. In cells loaded with H2-DCF-DA, plasma treatment increased total fluorescence in B16 melanoma cells compared to untreated controls (Figure 1(a)). Quantification of individual cellular fluorescence yielded a significantly enhanced mean fluorescence intensity (Figure 1(b)). To assess the cytotoxic effects, metabolic activity was assessed 3 hours after plasma treatment. Exposure to plasma for 60 s or 120 s but not 120 s of argon gas alone significantly decreased metabolic activity (Figure 1(c)). Subsequently, plasma-treated and control cells were imaged at different time points following in presence of PI indicative for cell membrane damage (Figure 2(a)). Utilization image-based quantification algorithms and the total number of cells as well as their mean fluorescence intensity of PI were determined (Figure 2(b)). Quantification and normalization to total cells revealed a significant increase in terminally dead cells in samples that had received 120 s of treatment (Figure 2(c)). Peak percent of dead cells was measured 12 h after treatment with a decrease after that. Altogether, plasma oxidized melanoma cells and decreased their metabolic activity by inducing terminal cell death.

3.2. Plasma Affected Cell Growth, Motility, and Biomechanical Properties

Next, total cell area and cell motility was assessed in PI (viable) cells. Total cell area was quantified at different time points postplasma treatment. Immediately following the treatment, the cell area was not affected (Figure 3(a)). By contrast, 60 s and 120 s of plasma treatment gave a significantly reduced cell area (Figures 3(b), 3(c), 3(d), and 3(e)). In the 120 s treated samples, the area was almost similar within the first hour (Figure 3(a)) compared to 6 h (Figure 3(b)) after treatment. This was not the case with all other samples where an increased cell area was observed. This suggested that also the viable cells were halting proliferation and possibly migration. Thus, the mean displacement of each viable cell was determined over three hours in controls and plasma-treated cells. In the 120 s plasma-treated sample, total displacement per viable cell was significantly decreased (Figure 3(f)). Concomitantly, mean nuclear area was significantly enlarged, arguing for cell cycle arrest. Both facts indicate decelerated cell motility, which is linked to biomechanical properties. Therefore, real-time deformability cytometry was performed in murine B16F10 control (Figure 4(a)) melanoma cells as well as following exposure to 60 s (Figure 4(b)) and 120 s (Figure 4(c)) of plasma treatment. After 60 s of plasma treatment, the median deformation and cell area changed from d = 0.041 to d = 0.027 and A = 216.6 μm2 to A = 202.6 μm2, respectively. A further reduction in median deformation to d = 0.02 was seen after 120 s of plasma treatment. This is summarized in Figure 4(d) by comparing the contour lines of each population. Overlay contour lines of each population clearly marked differences between all samples (Figure 4(d)). Application of an analytical model [25] allows for calculation of cellular properties. Significant differences were obtained between plasma-treated and control samples (Figure 4(e)). Sixty seconds of plasma treatment led to a significant increase in Young’s modulus from 1.53 ± 0.22 kPa to 1.79 ± 0.23 kPa. Plasma exposure of 120 s resulted in an even higher elastic modulus of 1.94 ± 0.26 kPa. This alteration in mechanical properties was accompanied by a small decrease in cell area from 243.6 ± 19.4 μm2 to 233.1 ± 19.1 μm2 (Figure 4(f)). An integral part of tight junction formation, membrane-associated ZO1 expression is inversely linked to motility. Immunofluorescence staining gave an increase in cytosolic staining of ZO1 3 h following plasma treatment (Figure 5(a)). This increase was significant even with short, nontoxic plasma treatment times (Figure 5(b)). We also stained melanoma cells with antibodies targeted against occludin and e-cadherin but staining was weak, and changes upon plasma treatment were not observed (data not shown). Altogether, plasma decreased melanoma cell growth, motility, and deformability together with an increased ZO1 expression.

3.3. Plasma Increased the Immunogenicity and Decreased VEGF Release in Melanomas

Successful melanoma therapy is strongly linked to immunomodulation. Therefore, the expression of several cell surface molecules was investigated 4 h and 24 h following plasma treatment. Representative overlay histograms are given for each protein and time point (Figure 6). With MHC I, a significant increase was not seen after 4 h (Figure 6(c)) but was seen after 24 h (Figure 6(d)) in 120 s plasma-treated samples. This pointed to an increase in antigen presentation promoting immune recognition. For MC-1R, an important receptor in melanocyte biology, a subtle but significant increase was seen 4 h (Figure 6(e)) and 24 h (Figure 6(f)) after plasma treatment. Calreticulin (CRT) is the key molecule in immunogenic cell death (ICD). CRT was significantly increased after both 4 h (Figure 6(i)) as well as 24 h (Figure 6(j)) following exposure to plasma. Angiogenesis is important for tumor blood supply. VEGF—being a major molecule in the formation of blood vessels—was significantly decreased (Figure 7) 24 h after plasma treatment. In our hands, VEGF decrease was greater than cell viable decrease (see Figure 2(d)).

4. Discussion

Cold plasma treatment affected melanoma cell viability, motility, and immunogenicity. Immunogenic properties such as therapy-induced upregulation MHCI and CRT are vital for antitumor immune responses [26]. MHCI is vital for presentation of endogenous and potentially tumor-specific (neo) antigens to cytotoxic T cells [27]. Vice versa, tumor cell elimination with high MHCI expression favors the generation of MHCIlow cancer cells, especially in metastasis [28]. Therefore, upregulation of MHCI is viewed as a therapeutic goal in many types of tumors [2931]. Similar to plasma, photodynamic therapy uses oxygen radicals and was shown to restore MHCI expression in human glioma [32]. Along similar lines, radiation upregulates MHCI expression in the breast [33], lung [34], and colon cancer [35]. Similar to downregulated MHCI, elevated levels of VEGF are also important for tumorigenesis [36]. We saw a drastic decrease in VEGF release likely owing to cellular toxicity. Nonetheless, an Akt-mediated increase in intracellular oxidants was previously linked to enhanced VEGF release [37]. Hence, VEGF release might be redox controlled, and its reduction would be therapeutically desired [38]. By enhancing immunogenicity, also CRT correlates with favorable prognosis for patients with, for example, lung cancer [39], gastric cancer [40], and leukemia [41]. CRT on melanoma cells was also involved in dendritic cell vaccination in melanoma patients, although cell death was found to be dispensable for that effect [42]. Exogenously added CRT also potentiates the immunogenicity of melanomas in patients [43]. A CRT fusion-protein added to B16 cells evoked an antitumor immune response in mice [44]. Intriguingly, therapeutic intervention associated with upregulation of CRT involves the generation of reactive species [4547].

Cold physical plasma expels reactive molecules known to be important in redox biology and medicine [48]. In contrast to intracellular generation with PDT and radio- or chemotherapy, plasma-generated species are applied exogenously from ambient air to cells and tissues [49]. kINPen plasma-generated reactive molecules include for example peroxynitrite, hydrogen peroxide, and hydroxyl radical [5052]. Today’s view is that most oxidative events in cells are translated by redox enzymes and thiol switches in transcription factors which then guide the cellular response [53]. For example, we previously identified activator protein 1 (AP1) family members such as FOSB and JUND in plasma-treated blood cancer cell lines to be crucial [54]. Both factors are redox-regulated [55], and their expression was dysregulated in metastatic melanoma [56]. This makes AP1 a crucial regulator of cell regulation and death [57], as observed in our study with a decrease in metabolic activity and cell cycle arrest and increase in terminally dead cells. Interestingly, JUN proteins are involved in melanoma migration [58].

Cell mechanics is a major regulator and indicator of cell function and motility [59]. The main structural component linking function to mechanical properties is the cytoskeleton consisting of filamentous actin, microtubules, and intermediate filaments. For migration, cells require to alter their morphology, which is controlled by the cytoskeleton on a molecular and the emerging mechanical properties on a cellular scale [60]. In real-time deformability cytometry, an increase in elastic modulus after plasma treatment was observed. This effect could be originated from an alteration in actin polymerization subject to redox control [61], which is also supported by the retarded migration of the cells. This is in agreement with an earlier study on fibroblasts where a direct correlation between cell elasticity and migration was shown [62]. Enhanced cell motility and therefore invasiveness correlates with increased cytosolic ZO1 protein whereas noninvasive breast cancer cells showed elevated ZO1 in the cell membrane [63]. In pancreatic cancer cells, however, membrane-associated ZO1 was supporting invasiveness [64]. In our work, we saw an increase of ZO1 not only in the cytosolic fraction but also visually in the cell membrane. This implicates a de novo translation of ZO1 proteins in melanoma cells and not necessarily its specific translocation from the membrane to the cytosol. Underlining this idea, de novo generated ZO1 in breast cancer cells was previously shown to be present in the cytosol as well as to translocate to the cell membrane [65]. Another report describes the association of melanoma ZO1 with adherence junctions of nonepithelial cells such as fibroblasts instead of tight junctions [66]. The authors concluded that knockdown of ZO1 suppresses melanoma invasiveness. Similarly, an upregulation of MC1R increases B16F10 melanoma motility [67]. Yet, the authors transfected MC1R and induced an about twentyfold increase. By contrast, MC1R upregulation after plasma was only 1.1-fold. The main function of MC1R is to control skin and hair pigmentation via eumelanin production [68]. MC1R is generally upregulated in melanoma cells [69]. This is used for therapeutic purposes to deliver target drugs into the cells, and pro-oxidant therapies such as PDT have been successfully employed in this strategy to increase survival in experimental animal models [70].

The utilization of only one cell line limits the specificity and/or generalization of our results that should be compared to nonmalignant melanocytes and confirmed in other cancer cell lines. Specifically, the relevance of our findings may increase if human cancer cells would be similarly affected. In addition, it would be valuable to identify the effects of other types of plasma sources in this model.

In summary, it was demonstrated that treatment of murine metastatic melanoma cells with cold physical plasma-derived oxidants exerted cytotoxic effects, decreased cell motility, and increased their immunogenicity. Animal models need to provide evidence whether plasma-inactivated melanoma experiences a vaccine-like immunogenic cell death (ICD) which would make plasma therapy an interesting new tool in oncology.

Conflicts of Interest

Oliver Otto is the cofounder and CEO of Zellmechanik Dresden GmbH Germany developing real-time deformability cytometry.

Acknowledgments

Funding was received from the German Federal Ministry of Education and Research (Grant nos. 03Z22DN11, 03Z22DN12, and 03Z22CN11).

References

  1. R. L. Siegel, K. D. Miller, and A. Jemal, “Cancer statistics, 2016,” CA: A Cancer Journal for Clinicians, vol. 66, pp. 7–30, 2016. View at: Google Scholar
  2. M. J. Smyth, S. F. Ngiow, A. Ribas, and M. W. Teng, “Combination cancer immunotherapies tailored to the tumour microenvironment,” Nature Reviews. Clinical Oncology, vol. 13, pp. 143–158, 2016. View at: Publisher Site | Google Scholar
  3. T. N. Schumacher and R. D. Schreiber, “Neoantigens in cancer immunotherapy,” Science, vol. 348, pp. 69–74, 2015. View at: Publisher Site | Google Scholar
  4. E. Quintana, E. Piskounova, M. Shackleton et al., “Human melanoma metastasis in NSG mice correlates with clinical outcome in patients,” Science Translational Medicine, vol. 4, p. 159ra149, 2012. View at: Publisher Site | Google Scholar
  5. T. A. Martin and W. G. Jiang, “Loss of tight junction barrier function and its role in cancer metastasis,” Biochimica et Biophysica Acta, vol. 1788, pp. 872–891, 2009. View at: Publisher Site | Google Scholar
  6. K. T. Flaherty, “Chemotherapy and targeted therapy combinations in advanced melanoma,” Clinical Cancer Research, vol. 12, pp. 2366s–2370s, 2006. View at: Publisher Site | Google Scholar
  7. A. E. Vilgelm, D. B. Johnson, and A. Richmond, “Combinatorial approach to cancer immunotherapy: strength in numbers,” Journal of Leukocyte Biology, vol. 100, pp. 275–290, 2016. View at: Publisher Site | Google Scholar
  8. S. Ladoire, L. Senovilla, D. Enot et al., “Biomarkers of immunogenic stress in metastases from melanoma patients: correlations with the immune infiltrate,” Oncoimmunology, vol. 5, article e1160193, 2016. View at: Google Scholar
  9. M. Obeid, A. Tesniere, F. Ghiringhelli et al., “Calreticulin exposure dictates the immunogenicity of cancer cell death,” Nature Medicine, vol. 13, pp. 54–61, 2007. View at: Google Scholar
  10. G. Kroemer, L. Galluzzi, O. Kepp, and L. Zitvogel, “Immunogenic cell death in cancer therapy,” Annual Review of Immunology, vol. 31, pp. 51–72, 2013. View at: Publisher Site | Google Scholar
  11. A. D. Garg, S. Martin, J. Golab, and P. Agostinis, “Danger signalling during cancer cell death: origins, plasticity and regulation,” Cell Death & Differentiation, vol. 21, pp. 26–38, 2014. View at: Google Scholar
  12. K. D. Weltmann and T. von Woedtke, “Plasma medicine-current state of research and medical application,” Plasma Physics and Controlled Fusion, vol. 59, p. 014031, 2017. View at: Publisher Site | Google Scholar
  13. S. Bekeschus, A. Schmidt, L. Bethge et al., “Redox stimulation of human THP-1 monocytes in response to cold physical plasma,” Oxidative Medicine & Cellular Longevity, vol. 2016, Article ID 5910695, 2016. View at: Google Scholar
  14. A. Zhunussova, E. A. Vitol, B. Polyak et al., “Mitochondria-mediated anticancer effects of non-thermal atmospheric plasma,” PloS One, vol. 11, article e0156818, 2016. View at: Google Scholar
  15. Y. Suzuki-Karasaki, “Tumor-targeting killing of multidrug-resistant human aggressive cancer cells by plasma-activated media via mitochondrial and endoplasmic reticulum damages,” International Journal of Molecular Medicine, vol. 38, pp. S50–S50, 2016. View at: Google Scholar
  16. J. Gay-Mimbrera, M. C. Garcia, B. Isla-Tejera, A. Rodero-Serrano, A. V. Garcia-Nieto, and J. Ruano, “Clinical and biological principles of cold atmospheric plasma application in skin cancer,” Advances in Therapy, vol. 33, pp. 894–909, 2016. View at: Publisher Site | Google Scholar
  17. D. Yan, J. H. Sherman, and M. Keidar, “Cold atmospheric plasma, a novel promising anti-cancer treatment modality,” Oncotarget, vol. 5, 2016. View at: Google Scholar
  18. V. Miller, A. Lin, and A. Fridman, “Why target immune cells for plasma treatment of cancer,” Plasma Chemistry and Plasma Processing, vol. 36, pp. 259–268, 2016. View at: Publisher Site | Google Scholar
  19. K. Le Gal, M. X. Ibrahim, C. Wiel et al., “Antioxidants can increase melanoma metastasis in mice,” Science Translational Medicine, vol. 7, p. 308re308, 2015. View at: Google Scholar
  20. K. Wende, S. Bekeschus, A. Schmidt et al., “Risk assessment of a cold argon plasma jet in respect to its mutagenicity,” Mutation Research, Genetic Toxicology and Environmental Mutagenesis, vol. 798-799, pp. 48–54, 2016. View at: Publisher Site | Google Scholar
  21. S. Kluge, S. Bekeschus, C. Bender et al., “Investigating the mutagenicity of a cold argon-plasma jet in an HET-MN model,” PloS One, vol. 11, article e0160667, 2016. View at: Google Scholar
  22. S. Bekeschus, A. Schmidt, K.-D. Weltmann, and T. von Woedtke, “The plasma jet kINPen – a powerful tool for wound healing,” Clinical Plasma Medicine, vol. 4, pp. 19–28, 2016. View at: Publisher Site | Google Scholar
  23. O. Otto, P. Rosendahl, A. Mietke et al., “Real-time deformability cytometry: on-the-fly cell mechanical phenotyping,” Nature Methods, vol. 12, pp. 199–202, 2015. View at: Publisher Site | Google Scholar
  24. M. Mokbel, D. Mokbel, A. Mietke et al., “Numerical simulation of real-time deformability cytometry to extract cell mechanical properties,” ACS Biomaterials Science & Engineering, 2017. View at: Publisher Site | Google Scholar
  25. A. Mietke, O. Otto, S. Girardo et al., “Extracting cell stiffness from real-time deformability cytometry: theory and experiment,” Biophysical Journal, vol. 109, pp. 2023–2036, 2015. View at: Publisher Site | Google Scholar
  26. H. Inoue and K. Tani, “Multimodal immunogenic cancer cell death as a consequence of anticancer cytotoxic treatments,” Cell Death & Differentiation, vol. 21, pp. 39–49, 2014. View at: Google Scholar
  27. C. M. Celluzzi, J. I. Mayordomo, W. J. Storkus, M. T. Lotze, and L. D. Falo Jr., “Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity,” The Journal of Experimental Medicine, vol. 183, pp. 283–287, 1996. View at: Publisher Site | Google Scholar
  28. E. Jager, M. Ringhoffer, M. Altmannsberger et al., “Immunoselection in vivo: independent loss of MHC class I and melanocyte differentiation antigen expression in metastatic melanoma,” International Journal of Cancer, vol. 71, pp. 142–147, 1997. View at: Publisher Site | Google Scholar
  29. V. Shetty, G. Sinnathamby, Z. Nickens et al., “MHC class I-presented lung cancer-associated tumor antigens identified by immunoproteomics analysis are targets for cancer-specific T cell response,” Journal of Proteomics, vol. 74, pp. 728–743, 2011. View at: Publisher Site | Google Scholar
  30. G. Ito, H. Tanaka, M. Ohira et al., “Correlation between efficacy of PSK postoperative adjuvant immunochemotherapy for gastric cancer and expression of MHC class I,” Experimental & Therapeutic Medicine, vol. 3, pp. 925–930, 2012. View at: Google Scholar
  31. A. Letsch, O. Elisseeva, C. Scheibenbogen et al., “Effect of vaccination of leukemia patients with a MHC class I peptide of Wilms tumor gene 1 (WT1) peptide with unspecific T helper stimulation on WT1-specific IgM responses and on IgG responses,” Journal of Clinical Oncology, vol. 26, pp. 3054–3054, 2008. View at: Publisher Site | Google Scholar
  32. S. Y. Zhang, J. L. Li, X. K. Xu, M. G. Zheng, C. C. Wen, and F. C. Li, “HMME-based PDT restores expression and function of transporter associated with antigen processing 1 (TAP1) and surface presentation of MHC class I antigen in human glioma,” Journal of Neuro-Oncology, vol. 105, pp. 199–210, 2011. View at: Publisher Site | Google Scholar
  33. S. Wan, S. Pestka, R. G. Jubin, Y. L. Lyu, Y. C. Tsai, and L. F. Liu, “Chemotherapeutics and radiation stimulate MHC class I expression through elevated interferon-beta signaling in breast cancer cells,” PloS One, vol. 7, article e32542, 2012. View at: Google Scholar
  34. X. Wang, J. E. Schoenhals, D. R. Valdecanas et al., “Suppression of major histocompatibility complex (MHC) class I and II mediates resistance to anti-PD-1 in lung adenocarcinoma tumors that can be overcome by radiation therapy,” International Journal of Radiation Oncology, Biology, Physics, vol. 96, p. S89, 2016. View at: Publisher Site | Google Scholar
  35. E. A. Reits, J. W. Hodge, C. A. Herberts et al., “Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy,” The Journal of Experimental Medicine, vol. 203, pp. 1259–1271, 2006. View at: Publisher Site | Google Scholar
  36. N. Oka, A. Soeda, A. Inagaki et al., “VEGF promotes tumorigenesis and angiogenesis of human glioblastoma stem cells,” Biochemical & Biophysical Research Communications, vol. 360, pp. 553–559, 2007. View at: Publisher Site | Google Scholar
  37. B. Govindarajan, J. E. Sligh, B. J. Vincent et al., “Overexpression of Akt converts radial growth melanoma to vertical growth melanoma,” The Journal of Clinical Investigation, vol. 117, pp. 719–729, 2007. View at: Publisher Site | Google Scholar
  38. J. M. Mehnert, M. M. McCarthy, L. Jilaveanu et al., “Quantitative expression of VEGF, VEGF-R1, VEGF-R2, and VEGF-R3 in melanoma tissue microarrays,” Human Pathology, vol. 41, pp. 375–384, 2010. View at: Publisher Site | Google Scholar
  39. J. Fucikova, E. Becht, K. Iribarren et al., “Calreticulin expression in human non-small cell lung cancers correlates with increased accumulation of antitumor immune cells and favorable prognosis,” Cancer Research, vol. 76, pp. 1746–1756, 2016. View at: Publisher Site | Google Scholar
  40. C. N. Chen, C. C. Chang, T. E. Su et al., “Identification of calreticulin as a prognosis marker and angiogenic regulator in human gastric cancer,” Annals of Surgical Oncology, vol. 16, pp. 524–533, 2009. View at: Publisher Site | Google Scholar
  41. J. Fucikova, I. Truxova, M. Hensler et al., “Calreticulin exposure by malignant blasts correlates with robust anticancer immunity and improved clinical outcome in AML patients,” Blood, vol. 128, pp. 3113–3124, 2016. View at: Publisher Site | Google Scholar
  42. A. N. Cornforth, A. W. Fowler, D. J. Carbonell, and R. O. Dillman, “Resistance to the proapoptotic effects of interferon-gamma on melanoma cells used in patient-specific dendritic cell immunotherapy is associated with improved overall survival,” Cancer Immunology, Immunotherapy, vol. 60, pp. 123–131, 2011. View at: Publisher Site | Google Scholar
  43. A. M. Dudek-Peric, G. B. Ferreira, A. Muchowicz et al., “Antitumor immunity triggered by melphalan is potentiated by melanoma cell surface-associated calreticulin,” Cancer Research, vol. 75, pp. 1603–1614, 2015. View at: Publisher Site | Google Scholar
  44. Y. Qin, Y. Han, C. Cao, Y. Ren, C. Li, and Y. Wang, “Melanoma B16-F1 cells coated with fusion protein of mouse calreticulin and virus G-protein coupled receptor induced the antitumor immune response in Balb/C mice,” Cancer Biology & Therapy, vol. 11, pp. 574–580, 2011. View at: Google Scholar
  45. M. Obeid, T. Panaretakis, N. Joza et al., “Calreticulin exposure is required for the immunogenicity of gamma-irradiation and UVC light-induced apoptosis,” Cell Death & Differentiation, vol. 14, pp. 1848–1850, 2007. View at: Publisher Site | Google Scholar
  46. M. E. Rodriguez, I. S. Cogno, L. S. Milla Sanabria, Y. S. Moran, and V. A. Rivarola, “Heat shock proteins in the context of photodynamic therapy: autophagy, apoptosis and immunogenic cell death,” Photochemical & Photobiological Sciences, vol. 15, pp. 1090–1102, 2016. View at: Publisher Site | Google Scholar
  47. T. Panaretakis, O. Kepp, U. Brockmeier et al., “Mechanisms of pre-apoptotic calreticulin exposure in immunogenic cell death,” The EMBO Journal, vol. 28, pp. 578–590, 2009. View at: Publisher Site | Google Scholar
  48. D. B. Graves, “The emerging role of reactive oxygen and nitrogen species in redox biology and some implications for plasma applications to medicine and biology,” Journal of Physics D-Applied Physics, vol. 45, article 263001, 2012. View at: Publisher Site | Google Scholar
  49. M. Dunnbier, A. Schmidt-Bleker, J. Winter et al., “Ambient air particle transport into the effluent of a cold atmospheric-pressure argon plasma jet investigated by molecular beam mass spectrometry,” Journal of Physics D-Applied Physics, vol. 46, article 435203, 2013. View at: Publisher Site | Google Scholar
  50. S. Bekeschus, S. Iseni, S. Reuter, K. Masur, and K. D. Weltmann, “Nitrogen shielding of an argon plasma jet and its effects on human immune cells,” IEEE Transactions on Plasma Science, vol. 43, pp. 776–781, 2015. View at: Publisher Site | Google Scholar
  51. H. Jablonowski and T. von Woedtke, “Research on plasma medicine-relevant plasma–liquid interaction: what happened in the past five years?” Clinical Plasma Medicine, vol. 3, pp. 42–52, 2015. View at: Publisher Site | Google Scholar
  52. S. Bekeschus, J. Kolata, C. Winterbourn et al., “Hydrogen peroxide: a central player in physical plasma-induced oxidative stress in human blood cells,” Free Radical Research, vol. 48, pp. 542–549, 2014. View at: Publisher Site | Google Scholar
  53. E. M. Hanschmann, J. R. Godoy, C. Berndt, C. Hudemann, and C. H. Lillig, “Thioredoxins, glutaredoxins, and peroxiredoxins—molecular mechanisms and health significance: from cofactors to antioxidants to redox signaling,” Antioxidants & Redox Signaling, vol. 19, pp. 1539–1605, 2013. View at: Publisher Site | Google Scholar
  54. A. Schmidt, K. Rödder, S. Hasse et al., “Redox-regulation of activator protein 1 family members in blood cancer cell lines exposed to cold physical plasma-treated medium,” Plasma Processes and Polymers, vol. 13, pp. 1179–1188, 2016. View at: Publisher Site | Google Scholar
  55. C. Abate, L. Patel, F. J. Rauscher 3rd, and T. Curran, “Redox regulation of fos and jun DNA-binding activity in vitro,” Science, vol. 249, pp. 1157–1161, 1990. View at: Publisher Site | Google Scholar
  56. D. T. Yamanishi, J. A. Buckmeier, and F. L. Meyskens Jr., “Expression of c-jun, jun-B, and c-fos proto-oncogenes in human primary melanocytes and metastatic melanomas,” The Journal of Investigative Dermatology, vol. 97, pp. 349–353, 1991. View at: Publisher Site | Google Scholar
  57. E. Shaulian and M. Karin, “AP-1 as a regulator of cell life and death,” Nature Cell Biology, vol. 4, pp. E131–E136, 2002. View at: Publisher Site | Google Scholar
  58. D. Wang, J. Y. Wang, N. Ding et al., “MAGE-A1 promotes melanoma proliferation and migration through C-JUN activation,” Biochemical & Biophysical Research Communications, vol. 473, pp. 959–965, 2016. View at: Publisher Site | Google Scholar
  59. C. J. Chan, A. E. Ekpenyong, S. Golfier et al., “Myosin II activity softens cells in suspension,” Biophysical Journal, vol. 108, pp. 1856–1869, 2015. View at: Publisher Site | Google Scholar
  60. J. Guck, F. Lautenschlager, S. Paschke, and M. Beil, “Critical review: cellular mechanobiology and amoeboid migration,” Integrative Biology (Camb), vol. 2, pp. 575–583, 2010. View at: Publisher Site | Google Scholar
  61. I. Dalle-Donne, R. Rossi, A. Milzani, P. Di Simplicio, and R. Colombo, “The actin cytoskeleton response to oxidants: from small heat shock protein phosphorylation to changes in the redox state of actin itself,” Free Radical Biology & Medicine, vol. 31, pp. 1624–1632, 2001. View at: Publisher Site | Google Scholar
  62. J. S. Lee, C. M. Hale, P. Panorchan et al., “Nuclear lamin A/C deficiency induces defects in cell mechanics, polarization, and migration,” Biophysical Journal, vol. 93, pp. 2542–2552, 2007. View at: Publisher Site | Google Scholar
  63. M. Polette, C. Gilles, B. Nawrocki-Raby et al., “Membrane-type 1 matrix metalloproteinase expression is regulated by zonula occludens-1 in human breast cancer cells,” Cancer Research, vol. 65, pp. 7691–7698, 2005. View at: Google Scholar
  64. E. Takai, X. Tan, Y. Tamori, M. Hirota, H. Egami, and M. Ogawa, “Correlation of translocation of tight junction protein zonula occludens-1 and activation of epidermal growth factor receptor in the regulation of invasion of pancreatic cancer cells,” International Journal of Oncology, vol. 27, pp. 645–651, 2005. View at: Google Scholar
  65. K. Aigner, B. Dampier, L. Descovich et al., “The transcription factor ZEB1 (deltaEF1) promotes tumour cell dedifferentiation by repressing master regulators of epithelial polarity,” Oncogene, vol. 26, pp. 6979–6988, 2007. View at: Publisher Site | Google Scholar
  66. K. S. Smalley, P. Brafford, N. K. Haass, J. M. Brandner, E. Brown, and M. Herlyn, “Up-regulated expression of zonula occludens protein-1 in human melanoma associates with N-cadherin and contributes to invasion and adhesion,” The American Journal of Pathology, vol. 166, pp. 1541–1554, 2005. View at: Publisher Site | Google Scholar
  67. H. Chung, J. H. Lee, D. Jeong, I. O. Han, and E. S. Oh, “Melanocortin 1 receptor regulates melanoma cell migration by controlling syndecan-2 expression,” The Journal of Biological Chemistry, vol. 287, pp. 19326–19335, 2012. View at: Publisher Site | Google Scholar
  68. J. Y. Lin and D. E. Fisher, “Melanocyte biology and skin pigmentation,” Nature, vol. 445, pp. 843–850, 2007. View at: Publisher Site | Google Scholar
  69. A. A. Rosenkranz, T. A. Slastnikova, M. O. Durymanov, and A. S. Sobolev, “Malignant melanoma and melanocortin 1 receptor,” Biochemistry (Mosc), vol. 78, pp. 1228–1237, 2013. View at: Publisher Site | Google Scholar
  70. T. A. Slastnikova, A. A. Rosenkranz, T. N. Lupanova, P. V. Gulak, N. V. Gnuchev, and A. S. Sobolev, “Study of efficiency of the modular nanotransporter for targeted delivery of photosensitizers to melanoma cell nuclei in vivo,” Doklady. Biochemistry and Biophysics, vol. 446, pp. 235–237, 2012. View at: Publisher Site | Google Scholar

Copyright © 2017 Sander Bekeschus et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

784 Views | 597 Downloads | 25 Citations
 PDF  Download Citation  Citation
 Download other formatsMore
 Order printed copiesOrder